Travel Vaccines Market Report 2026

Travel Vaccines Market Overview

• Travel Vaccines market size has reached to $5.09 billion in 2025 • Expected to grow to $8.16 billion in 2030 at a compound annual growth rate (CAGR) of 10% • Growth Driver: Surge In Travel And Tourism Drives Growth Of The Travel Vaccine Market • Market Trend: Innovative Travel Vaccines Prevent Hepatitis A For Travelers And Children • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Travel Vaccines Market?

Travel vaccines are vaccines to protect against diseases that are either indigenous to the country of origin or the country of destination. They function to safeguard travelers and stop the spread of disease both within and between nations. The main travel vaccines available to treat diseases include hepatitis A, diphtheria, pertussis, and tetanus (DPT), yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal, and others. Hepatitis A is a disease caused by the hepatitis A virus (HAV), which results in inflammation of the liver. They are composed of mono vaccines and combination vaccines booked by online booking, in-person booking channels for domestic travel, and outbound travel applications.

What Is The Travel Vaccines Market Growth Forecast?

The travel vaccines market size is expected to see rapid growth in the next few years. It will grow to $8.16 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing global travel and mobility, advancements in biotechnology for combination vaccines, growth of digital health and telemedicine services, rising awareness of preventive healthcare, expansion of international travel immunization programs. Major trends in the forecast period include rise in international tourism and business travel, increasing awareness of preventive healthcare for travelers, expansion of online travel health services and booking platforms, development of combination and multivalent travel vaccines, growth in public-private partnerships for global immunization programs.

Global Travel Vaccines Market Segmentation

1) By Disease: Hepatitis A, Diphtheria, Pertussis, And Tetanus (DPT), Yellow Fever, Typhoid, Hepatitis B, Measles And Mumps, Rabies, Meningococcal, Other Diseases, 2) By Composition: Mono Vaccines, Combination Vaccines 3) By Booking Channel: Online Booking, In-Person Booking 4) By Application: Domestic Travel, Outbound Travel

What Is The Driver Of The Travel Vaccines Market?

The increase in travel and tourism is expected to propel the growth of the travel vaccine market going forward. Travel and tourism refer to the movement of people or things, including vehicles like trains, boats, airplanes, and other conveyances, between various remote geographic areas. Travel vaccines are helpful for tourists and travelers by keeping them safe and healthy while they are traveling abroad. For instance, in May 2025, according to UN Tourism, a Spain-based specialized agency responsible for the promotion of responsible, sustainable, and universally accessible tourism, in the first three months of 2025, over 300 million tourists traveled internationally, about 14 million more than during the same period in 2024, which marks a 5% year-on-year increase. Therefore, the increase in travel and tourism is driving the growth of the travel vaccine industry.

Key Players In The Global Travel Vaccines Market

Major companies operating in the travel vaccines market are Pfizer Inc, Johnson and Johnson, Merck & Co. Inc, Sanofi SA, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Panacea Biotec, Bharat Biotech International Limited, Bio Farma, Novavax Inc, Emergent BioSolutions UK, Biological E. Limited, Vabiotech, Cadila Healthcare Limited, Zydus Lifesciences Ltd, Cipla Inc, Haffkine Biopharmaceutical Corporation Ltd

Global Travel Vaccines Market Trends and Insights

Major companies operating in the travel vaccine market are developing innovative vaccines to provide active immunization to prevent Hepatitis A common concern for travelers. A travel vaccine is a vaccine specifically designed to protect individuals from infectious diseases that are prevalent in certain regions or countries, often recommended for travelers visiting those areas. For instance, in January 2024, Indian Immunologicals Ltd. (IIL), an India-based biotechnology company, launched Havisure, India’s first indigenously developed Hepatitis A vaccine. Havisure is anticipated to be instrumental in providing protection against the Hepatitis A virus, which mainly impacts the liver. This vaccine is effective in preventing the disease and is advised for children as part of routine immunization. Additionally, it is recommended for individuals at risk of exposure or those traveling to areas with high rates of hepatitis A.

What Are Latest Mergers And Acquisitions In The Travel Vaccines Market?

In May 2023, Bavarian Nordic, a US-based biopharmaceutical company, acquired Emergent BioSolutions’ travel vaccine portfolio for an undisclosed amount. With the acquisition, Bavarian Nordic gained two commercially available vaccines-Vivotif for the prevention of typhoid fever and Vaxchora for the prevention of cholera, as well as a Phase 3 vaccine candidate for the prevention of the Chikungunya virus. The acquisition also includes US-based R&D facilities, a Swiss biologics production facility, and EU and US commercial operations with a specialized salesforce. Emergent BioSolutions is a US-based biotechnology firm that specializes in manufacturing and developing devices, vaccines, therapeutics, and contract manufacturing and travel vaccines is a business division of the company.

Regional Insights

North America was the largest region in the travel vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Travel Vaccines Market?

The travel vaccine market consists of sales of vaccines for diseases such as Japanese encephalitis, tick-borne encephalitis, and tuberculosis (TB). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Travel Vaccines Market Report 2026?

The travel vaccines market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the travel vaccines industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.